Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and...
Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeutics PR Newswire NEW YORK, July 1, 2016 NEW YORK, July 1, 2016...
Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ: SNTA) announced today that the annual meeting of stockholders to approve, among other things, the merger agreement with Madrigal...
Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, M.D., designated Chairman and...
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics PR Newswire NEW YORK, May 27, 2016 NEW YORK, May 27, 2016 /PRNewswire/ -- At present, the Biotech...
– Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies – – Paul A. Friedman, M.D. Named Chairman and Chief Executive Officer of Combined Company – –...
Announces Reduction in Force, Appointment of Scott Morenstein to Board of Directors Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended...
Company to Host Conference Call on Wednesday, October 21 at 8:00 AM ET Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the formation of an Expert Oncology Panel to provide guidance on research and development strategies for the Company’s portfolio of...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Alan C. Rigby, Ph.D., as the Company’s Senior Vice President and Chief Scientific Officer. Dr. Rigby brings over...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.005 | 0.01 | 0.005 | 91250 | 0.00570582 | CS |
| 26 | -0.01 | -66.6666666667 | 0.015 | 0.02 | 0.005 | 141390 | 0.00998411 | CS |
| 52 | -0.015 | -75 | 0.02 | 0.045 | 0.005 | 128594 | 0.0154035 | CS |
| 156 | -0.245 | -98 | 0.25 | 0.53 | 0.005 | 63374 | 0.09822455 | CS |
| 260 | -0.245 | -98 | 0.25 | 0.53 | 0.005 | 63374 | 0.09822455 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
